Sequenom in Discussions with FDA on Premarket Application for Sequencing-Based Trisomy 21 Test

CEO Harry Hixson said that the company had its first meeting with the FDA regarding the test in January, and while he could not comment on specifics of the meeting, in response to an investor question, he said that "it's safe to say that [the FDA] has not raised any concerns."

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.